153 related articles for article (PubMed ID: 27211906)
41. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
42. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.
Mateo F; Arenas EJ; Aguilar H; Serra-Musach J; de Garibay GR; Boni J; Maicas M; Du S; Iorio F; Herranz-Ors C; Islam A; Prado X; Llorente A; Petit A; Vidal A; Català I; Soler T; Venturas G; Rojo-Sebastian A; Serra H; Cuadras D; Blanco I; Lozano J; Canals F; Sieuwerts AM; de Weerd V; Look MP; Puertas S; García N; Perkins AS; Bonifaci N; Skowron M; Gómez-Baldó L; Hernández V; Martínez-Aranda A; Martínez-Iniesta M; Serrat X; Cerón J; Brunet J; Barretina MP; Gil M; Falo C; Fernández A; Morilla I; Pernas S; Plà MJ; Andreu X; Seguí MA; Ballester R; Castellà E; Nellist M; Morales S; Valls J; Velasco A; Matias-Guiu X; Figueras A; Sánchez-Mut JV; Sánchez-Céspedes M; Cordero A; Gómez-Miragaya J; Palomero L; Gómez A; Gajewski TF; Cohen EEW; Jesiotr M; Bodnar L; Quintela-Fandino M; López-Bigas N; Valdés-Mas R; Puente XS; Viñals F; Casanovas O; Graupera M; Hernández-Losa J; Ramón Y Cajal S; García-Alonso L; Saez-Rodriguez J; Esteller M; Sierra A; Martín-Martín N; Matheu A; Carracedo A; González-Suárez E; Nanjundan M; Cortés J; Lázaro C; Odero MD; Martens JWM; Moreno-Bueno G; Barcellos-Hoff MH; Villanueva A; Gomis RR; Pujana MA
Oncogene; 2017 May; 36(19):2737-2749. PubMed ID: 27991928
[TBL] [Abstract][Full Text] [Related]
43. Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.
Zhou J; Luo J; Wu K; Yun EJ; Kapur P; Pong RC; Du Y; Wang B; Authement C; Hernandez E; Yang J; Xiao G; Cha TL; Wu HC; Wu D; Margulis V; Lotan Y; Brugarolas J; He D; Hsieh JT
Oncogene; 2016 Sep; 35(35):4663-74. PubMed ID: 26876207
[TBL] [Abstract][Full Text] [Related]
44. Placental DEPTOR as a stress sensor during pregnancy.
Mparmpakas D; Zachariades E; Goumenou A; Gidron Y; Karteris E
Clin Sci (Lond); 2012 Apr; 122(7):349-59. PubMed ID: 21992080
[TBL] [Abstract][Full Text] [Related]
45. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.
Shi Y; Daniels-Wells TR; Frost P; Lee J; Finn RS; Bardeleben C; Penichet ML; Jung ME; Gera J; Lichtenstein A
Cancer Res; 2016 Oct; 76(19):5822-5831. PubMed ID: 27530328
[TBL] [Abstract][Full Text] [Related]
46. Comparison of the effects of synthetic and plant-derived mTOR regulators on healthy human ovarian cells.
Sirotkin AV; Adamcova E; Rotili D; Mai A; Mlyncek M; Mansour L; Alwasel S; Harrath AH
Eur J Pharmacol; 2019 Jul; 854():70-78. PubMed ID: 30959047
[TBL] [Abstract][Full Text] [Related]
47. Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-κB pathway.
Chen Y; Wang X; Duan C; Chen J; Su M; Jin Y; Deng Y; Wang D; Chen C; Zhou L; Cheng J; Wang W; Xi Q
Cell Prolif; 2016 Dec; 49(6):657-668. PubMed ID: 27651027
[TBL] [Abstract][Full Text] [Related]
48. Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.
Sato M; Kawana K; Adachi K; Fujimoto A; Yoshida M; Nakamura H; Nishida H; Inoue T; Taguchi A; Ogishima J; Eguchi S; Yamashita A; Tomio K; Wada-Hiraike O; Oda K; Nagamatsu T; Osuga Y; Fujii T
Int J Oncol; 2017 Apr; 50(4):1431-1438. PubMed ID: 28259988
[TBL] [Abstract][Full Text] [Related]
49. [Antiproliferation of cardamonin associated with mRNA expression of mTOR, Raptor and Rictor].
Zheng W; Shi D; Ji X; Han Y; Liao Q
Zhongguo Zhong Yao Za Zhi; 2010 Sep; 35(17):2318-23. PubMed ID: 21137347
[TBL] [Abstract][Full Text] [Related]
50. Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression.
Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
In Vitro Cell Dev Biol Anim; 2016 Jan; 52(1):45-8. PubMed ID: 26427711
[TBL] [Abstract][Full Text] [Related]
51. The human myometrium differentially expresses mTOR signalling components before and during pregnancy: evidence for regulation by progesterone.
Foster HA; Davies J; Pink RC; Turkcigdem S; Goumenou A; Carter DR; Saunders NJ; Thomas P; Karteris E
J Steroid Biochem Mol Biol; 2014 Jan; 139():166-72. PubMed ID: 23541542
[TBL] [Abstract][Full Text] [Related]
52. Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys.
Kawata Y; Nagasaka K; Oda K; Makii C; Takeuchi M; Oki S; Honjo H; Kojima M; Miyagawa Y; Taguchi A; Tanikawa M; Sone K; Hiraike H; Matsumoto Y; Wada-Hiraike O; Ayabe T; Osuga Y; Fujii T
Cancer Sci; 2020 Oct; 111(10):3824-3834. PubMed ID: 32713096
[TBL] [Abstract][Full Text] [Related]
53. LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells.
Wei Y; Han T; Wang R; Wei J; Peng K; Lin Q; Shao G
Oncol Rep; 2018 Jul; 40(1):425-433. PubMed ID: 29749504
[TBL] [Abstract][Full Text] [Related]
54. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
[TBL] [Abstract][Full Text] [Related]
55. Alteration in the mRNA expression profile of the autophagy-related mTOR pathway in schizophrenia patients treated with olanzapine.
Cui F; Gu S; Gu Y; Yin J; Fang C; Liu L
BMC Psychiatry; 2021 Aug; 21(1):388. PubMed ID: 34348681
[TBL] [Abstract][Full Text] [Related]
56. ESC-3 induces apoptosis of human ovarian carcinomas through Wnt/β-catenin and Notch signaling in vitro and in vivo.
Fu QR; Song W; Deng YT; Li HL; Mao XM; Lin CL; Zheng YH; Chen SM; Chen QH; Chen QX
Int J Oncol; 2017 Jan; 50(1):241-251. PubMed ID: 27878242
[TBL] [Abstract][Full Text] [Related]
57. Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway.
Yuan L; Sheng X; Willson AK; Roque DR; Stine JE; Guo H; Jones HM; Zhou C; Bae-Jump VL
Endocr Relat Cancer; 2015 Aug; 22(4):577-91. PubMed ID: 26045471
[TBL] [Abstract][Full Text] [Related]
58. An evolving role for DEPTOR in tumor development and progression.
Wang Z; Zhong J; Inuzuka H; Gao D; Shaik S; Sarkar FH; Wei W
Neoplasia; 2012 May; 14(5):368-75. PubMed ID: 22745583
[TBL] [Abstract][Full Text] [Related]
59. A study of zederone for the inhibition on ovarian cancer cell proliferation through mTOR/p70s6K signalling pathway.
Zhang Z; Li L; Wang J; Liang X; Wang Y; Wang X; Qiao Y; Zhao B
J BUON; 2020; 25(2):785-791. PubMed ID: 32521868
[TBL] [Abstract][Full Text] [Related]
60. Utility of mTOR inhibition in hematologic malignancies.
Younes A; Samad N
Oncologist; 2011; 16(6):730-41. PubMed ID: 21632450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
